We are happy to announce the recent acquisition of the TransQST partner OcellO by Crown Bioscience (CrownBio), a JSR Life Sciences global drug discovery and development service company, providing translational platforms to advance oncology, immuno-oncology, and inflammatory disorders. With this acquisition, which will contribute to make both companies stronger and more competitive, CrownBio will officially become a member of our consortium.

The combined service portfolio of the companies gets expanded by this union. OcellO will provide expertise in high content imaging, while CrownBio will bring in their advanced in vitro and in vivo screening and immunotherapy assessment services. The acquisition also contributes to the expansion of OcellO’s facilities at their Leiden site both in lab space and in access to new technologies, as well as in terms of creating new jobs.

Since its creation in 2011, OcellO has been known for its customer commitment and its core principles of innovation and quality. These values will remain as part of its essence when joining CrownBio.

We send our very best wishes and congratulations to the OcellO crew in this new stage and welcome them aboard of the consortium as CrownBio. TransQST is glad to be part of this success story.